Serum neudesin is elevated in pregnancies complicated by pregestational type 2 diabetes: an exploratory cross-sectional controlled study
- 1Ankara Etlik City Hospital Internal Medicine, Ankara, Turkey
- 2Ankara Etlik City Hospital Medical Biochemistry, Ankara, Turkey
Abstract
Objective: Neudesin has been linked to adipose tissue activity, glucose metabolism, and insulin resistance. Evidence on its behavior in diabetic pregnancies is limited, particularly in women with pregestational type 2 diabetes mellitus (PREGDM). This exploratory cross-sectional controlled study evaluated serum neudesin concentrations in pregnancies complicated by pregestational type 2 diabetes mellitus (PREGDM) or gestational diabetes mellitus (GDM), and in non-diabetic pregnant controls without major systemic disease, while examining the influence of gestational timing.
Methods: This study included 90 pregnant women: 30 with PREGDM, 30 with GDM, and 30 non-diabetic controls without major systemic disease. Controls were recruited in two planned gestational-age strata, including early pregnancy and 24–28 weeks, to provide clinically relevant timing-aware comparisons. Serum neudesin concentrations were measured using a human neudesin enzyme-linked immunosorbent assay kit (BT LAB, catalogue no. E4258Hu) and reported as ng/mL. Overall group comparisons were supplemented by gestational-timing-aware analyses and exploratory multivariable log-neudesin regression.
Results: Overall median serum neudesin was highest in the PREGDM group (5.67 [4.72–6.21] ng/mL), followed by the GDM group (2.80 [2.70–3.10] ng/mL) and controls (2.17 [1.77–2.89] ng/mL; p < 0.001). In gestational-timing-aware comparisons, PREGDM remained higher than early-pregnancy controls (5.67 [4.72–6.21] vs. 1.70 [1.37–2.15] ng/mL; Hodges–Lehmann difference, 3.70 ng/mL; 95% CI, 3.15–4.35; p < 0.001). In contrast, GDM did not differ from controls sampled at 24–28 weeks (2.80 [2.70–3.10] vs. 2.85 [2.28–3.03] ng/mL; Hodges–Lehmann difference, 0.04 ng/mL; 95% CI, − 0.20 to 0.40; p = 0.791). In the diabetic-only model adjusted for gestational age and age, the PREGDM-GDM contrast was attenuated (GMR, 1.31; 95% CI, 0.61–2.85; p = 0.490). In the all-participant adjusted model, PREGDM remained associated with higher neudesin than controls (GMR, 3.11; 95% CI, 2.57–3.76; p < 0.001), whereas the GDM-control contrast was not significant (GMR, 1.12; 95% CI, 0.96–1.30; p = 0.149).
Conclusion: Serum neudesin was most consistently elevated in pregnancies complicated by PREGDM. The apparent overall GDM-control difference was not retained after timing-aware comparison or adjustment. Given the modest sample size, neudesin should be considered an exploratory complementary metabolic marker rather than a standalone diagnostic biomarker.
Related
- Maternal and Antenatal Complications in Pregnancies Complicated by Fetal Intra-Abdominal Umbilical Vein Varix
- Maternal and Perinatal Outcomes in Pregnancies Complicated by Predominantly Benign Ovarian Lesions: A Retrospective Case-Control Study of 305 Pregnancies
- Fetal and neonatal outcomes of pregnancies complicated by maternal sleep-disordered breathing: a systematic review.
- AI-Powered CURA Application for Identifying At-Risk Pregnancies in Obstetrics Management (CURAte): protocol for a randomised controlled trial.
- Analysis of Double-Lumen Irrigation-Suction Tube in Patients With Severe Acute Pancreatitis Complicated by Acute Respiratory Distress Syndrome: A Single-Center Exploratory Retrospective Study Using Propensity Score Matching
BibTeX
@article{koksal2026serum,
title = {{Serum neudesin is elevated in pregnancies complicated by pregestational type 2 diabetes: an exploratory cross-sectional controlled study}},
author = {Zuhal Köksal and Funda Güçel and Şeyma Sarışen},
journal = {BMC Pregnancy and Childbirth},
year = {2026},
month = jul,
doi = {10.1186/s12884-026-09743-5},
url = {https://doi.org/10.1186/s12884-026-09743-5},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Serum neudesin is elevated in pregnancies complicated by pregestational type 2 diabetes: an exploratory cross-sectional controlled study
AU - Zuhal Köksal
AU - Funda Güçel
AU - Şeyma Sarışen
PY - 2026
DA - 2026/07/31
JO - BMC Pregnancy and Childbirth
DO - 10.1186/s12884-026-09743-5
UR - https://doi.org/10.1186/s12884-026-09743-5
AB - Objective: Neudesin has been linked to adipose tissue activity, glucose metabolism, and insulin resistance. Evidence on its behavior in diabetic pregnancies is limited, particularly in women with pregestational type 2 diabetes mellitus (PREGDM). This exploratory cross-sectional controlled study evaluated serum neudesin concentrations in pregnancies complicated by pregestational type 2 diabetes mellitus (PREGDM) or gestational diabetes mellitus (GDM), and in non-diabetic pregnant controls without major systemic disease, while examining the influence of gestational timing. Methods: This study included 90 pregnant women: 30 with PREGDM, 30 with GDM, and 30 non-diabetic controls without major systemic disease. Controls were recruited in two planned gestational-age strata, including early pregnancy and 24–28 weeks, to provide clinically relevant timing-aware comparisons. Serum neudesin concentrations were measured using a human neudesin enzyme-linked immunosorbent assay kit (BT LAB, catalogue no. E4258Hu) and reported as ng/mL. Overall group comparisons were supplemented by gestational-timing-aware analyses and exploratory multivariable log-neudesin regression. Results: Overall median serum neudesin was highest in the PREGDM group (5.67 [4.72–6.21] ng/mL), followed by the GDM group (2.80 [2.70–3.10] ng/mL) and controls (2.17 [1.77–2.89] ng/mL; p < 0.001). In gestational-timing-aware comparisons, PREGDM remained higher than early-pregnancy controls (5.67 [4.72–6.21] vs. 1.70 [1.37–2.15] ng/mL; Hodges–Lehmann difference, 3.70 ng/mL; 95% CI, 3.15–4.35; p < 0.001). In contrast, GDM did not differ from controls sampled at 24–28 weeks (2.80 [2.70–3.10] vs. 2.85 [2.28–3.03] ng/mL; Hodges–Lehmann difference, 0.04 ng/mL; 95% CI, − 0.20 to 0.40; p = 0.791). In the diabetic-only model adjusted for gestational age and age, the PREGDM-GDM contrast was attenuated (GMR, 1.31; 95% CI, 0.61–2.85; p = 0.490). In the all-participant adjusted model, PREGDM remained associated with higher neudesin than controls (GMR, 3.11; 95% CI, 2.57–3.76; p < 0.001), whereas the GDM-control contrast was not significant (GMR, 1.12; 95% CI, 0.96–1.30; p = 0.149). Conclusion: Serum neudesin was most consistently elevated in pregnancies complicated by PREGDM. The apparent overall GDM-control difference was not retained after timing-aware comparison or adjustment. Given the modest sample size, neudesin should be considered an exploratory complementary metabolic marker rather than a standalone diagnostic biomarker.
SN - 1471-2393
ER -